Targeting the intra-erythrocytic life cycle of Plasmodium falciparum unveils antimalarial drug discovery starting points from Drymaria cordata and Macaranga monandra

J Ethnopharmacol. 2026 Jan 10:354:120518. doi: 10.1016/j.jep.2025.120518. Epub 2025 Sep 1.

Abstract

Ethnopharmacological relevance: Drymaria cordata and Macaranga monandra are two medicinal plants traditionally used in Cameroon to treat malaria, but their scientific validation remains unclear.

Aim of the study: To validate the antiplasmodial action of extracts and fractions derived from Drymaria cordata and Macaranga monandra.

Materials and methods: Aqueous, methanolic, ethanolic, and hydroethanolic extracts of D. cordata (whole plant) and M. monandra (bark) were prepared by maceration followed by liquid-liquid partition of actives. Extracts and fractions were screened against chloroquine-sensitive (Pf3D7) and multidrug-resistant (PfDd2) strains of P. falciparum, while selectivity was determined on Vero cells. Stage-specific analysis and killing dynamics of potent fractions were profiled, complemented with UHPLC-MS analysis coupled to in silico prediction of pharmacokinetics of identified metabolites.

Results: D. cordata ethanolic extract showed moderate activity (IC50PfDd2: 18.9 μg/mL; IC50Pf3D7: 24.51 μg/mL), while all four M. monandra extracts exhibited good activity (IC50 < 8 μg/mL). The methanolic bark extract (MMBME) was highly potent and selective (IC50PfDd2: 2.46 μg/mL, SI > 203; IC50Pf3D7: 1.02 μg/mL, SI > 487). Fractionation yielded two active fractions from MMBME: F2 (IC50PfDd2: 0.60 μg/mL, IC50Pf3D7: 3.42 μg/mL) and F3 (IC50PfDd2: 0.92 μg/mL, IC50Pf3D7: 2.46 μg/mL). Fractions F2 and F3 arrested ring-stage development, lysed trophozoite-infected red blood cells, and blocked merozoite egress. UHPLC-MS analysis identified 17 metabolites in fractions F2 and F3, including fatty acyls, flavonoids, phenols, terpenes, and coumarins. Lecanoric acid was predicted as a promising antimalarial candidate.

Conclusions: Macaranga monandra bark fractions F2 and F3 are potent sources of antiplasmodial compounds targeting multiple asexual blood stages (ABS).

Keywords: Drymaria cordata; In silico prediction; In vitro efficacy; Macaranga monandra; Pharmacodynamics; Plasmodium falciparum.

MeSH terms

  • Animals
  • Antimalarials* / isolation & purification
  • Antimalarials* / pharmacology
  • Cameroon
  • Chlorocebus aethiops
  • Drug Discovery
  • Erythrocytes* / drug effects
  • Erythrocytes* / parasitology
  • Life Cycle Stages / drug effects
  • Plant Extracts* / isolation & purification
  • Plant Extracts* / pharmacology
  • Plasmodium falciparum* / drug effects
  • Plasmodium falciparum* / growth & development
  • Vero Cells

Substances

  • Antimalarials
  • Plant Extracts